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1. INTRODUCTION 
Anaerobic bacteria have been of microbiological and clinical interest since Louis 
Pasteur's use of the word "anaerobies" to describe his isolation and description of "septic 
vibrio" (Clostridium septicum). More than 100 years has passed since then, accompanied by 
ever expanding knowledge about anaerobic bacteria, their pathogenicity and the wide 
spectrum of anaerobic infections caused by both invasion and intoxication. Anaerobic bacteria 
are widely distributed in nature in oxygen-free habitats. Many members of the indigenous 
human flora are anaerobic bacteria, including spirochetes and Gram-positive and Gram-
negative cocci and rods. Anaerobic bacteria are important pathogens in a wide variety of 
infections throughout the human body. They generally originate from the patient's indigenous 
flora and they may be involved in essentially any type of bacterial infection in humans. 
They play an important role in the most commonly encountered categories of 
infection: osteomyelitis and skin and soft tissue, pleuropulmonary, intraabdominal and female 
genital tract infections. Most often they are part of a mixed flora, but some infections involve 
only anaerobes. The severity of anaerobic or mixed anaerobic infections is quite variable, 
ranging from very low grade (even inapparent) infection to rapidly progressive infection with 
a significant mortality rate. Infections involving anaerobic bacteria are characterized in 
particular by a tendency towards suppuration or abscess formation and the production of 
tissue necrosis. Proliferation of anaerobic bacteria in tissue depends on the absense of oxygen. 
Oxygen is excluded from the tissue when the local blood supply is impaired by trauma, 
obstruction or surgical manipulation. Anaerobes multiply well in dead tissue. The 
multiplication of aerobic or facultative organisms in association with anaerobes in infected 
tissue also diminishes the oxygen concentration and develops a habitat that supports the 
growth of anaerobic bacteria. 
Clostridium difficile is recognized as the major infectious agent responsible for 
nosocomial diarrhoea and potentially lethal pseudomembranous colitis (PMC) following 
antimicrobial therapy. Disease may be associated with a spectrum of severity, ranging from 
mild diarrhoea (most common), through moderately severe disease with watery diarrhoea, 
abdominal pain and a systemic upset, life-threatening and sometimes fatal PMC. This may be 
accompanied by toxic megacolon (rare), an electrolyte imbalance and occasional bowel 
perforation. One of the most remarkable characteristics of such diseases is that, in almost all 
cases, they occur following antibiotic therapy. Cumulative researches pointed the finger of 
suspicion at toxin-producing C. difficile as an important cause of nosocomial morbidity and 
mortality. At this time, elucidation of this "new" gut pathogen presented a challenge to 
diagnostic clinical microbiology laboratories, which, as time progressed, were met with 
increasing requests to investigate stool specimens for evidence of C. difficile. The rate of C. 
difficile acquisition varies with the patient population studied, the use of antibiotics and the 
presence of an outbreak in the ward studied. In the absence of an outbreak, the acquisition rate 
has been estimated at 4-21%, but this acquisition remains asymptomatic in more than 63% of 
the cases. Nevertheless, during outbreaks, higher acquisition rates have been observed, such 
as 32% in the study performed by Delmee in a haematology ward. 
The laboratory isolation and identification of nosocomial C. difficile strains have 
necessitated the development of typing methods to provide a better follow-up of the 
epidemiology of the disease and to afford a better insight into the pathogenicity of various 
strains. Numerous typing methods have been developed on the basis of various phenotypic 
and genotyping markers of this organism in order to understand the nosocomial epidemiology 
of C. difficile infection. Molecular typing methods are generally regarded as superior to 
phenotypic methods in terms of the stability of expression and the greater degrees of 
typeability, and a number of methods have been applied to C. difficile. PCR ribotyping uses 
specific primers complementary to sites within the RNA operon, it was first applied to C. 
difficile by Gurtler, who targeted the amplification process at the spacer region between the 
16S and 23S rRNA regions. This part of the genome has been shown to be very 
heterogeneous, in contrast with the rRNA genes themselves, which are highly conserved. C. 
difficile has been demonstrated to possess multiple copies of the rRNA genes in its genome, 
which vary not only in number between strains, but also in size between different copies on 
the same genome. 
Members of the Bacteroides fragilis group of anaerobes are the most frequently 
encountered anaerobic pathogens in clinical infections, and play the most important role of 
poly- or sometimes monobacterial infections. Bacteroides spp. are major constituents of the 
normal colonic microflora, and are also found in smaller numbers in the female genital tract, 
but are not common in the mouth or upper respiratory tract. The colon contains the largest 
total populations of microorganisms of any inhabited region of the human body. The 
Bacteroides are the most numerous members of the normal microbiota in the lower intestine, 
representing nearly 1011 cells per gram of faeces (dry weight). B. vulgatus, B. 
thetaiotaomicron and B. distasonis are numerically dominant in the normal colonic flora, with 
only 1 to 5 % of the cultivable colonic bacteria comprising B. fragilis, although this figure has 
been challenged as being an underestimate. While the Bacteroides are the predominant 
members of the flora of the lower intestine, they are also opportunistic pathogens causing 
infections in body sites other than the large bowel, where they normally reside. These 
infections are primarily situated close to the colon. The Bacteroides are involved in ca. 80% 
of all human anaerobic infections, where B. fragilis is the most frequent causative agent, 
despite its low abundance in the intestine. The most common infections associated with them 
are intraabdominal abscesses, peritonitis and wound infections of the large intestine. 
Bacteroides spp. are also the principal pathogens of the female genital tract and pelvic 
inflammatory abscesses and are implicated in anaerobic pulmonary abscesses. B. fragilis is 
frequently involved in brain abscesses secondary to chronic otitis media, and is a major 
pathogen in cases of diabetic foot ulcer syndrome. 
However, antibiotic resistance is increasingly common among the members of this 
group. Knowledge of the status and the mechanisms of resistance is critical for both the 
selection of antimicrobial therapy and the design of new antimocrobial agents. Five groups of 
antimicrobial agents are active against most of the anaerobic bacteria of clinical importance. 
These are nitroimidazoles, such as metronidazole or tinidazole, carbapenems, such as 
imipenem or meropenem, or more recently faropenem, amphenicols such as chloramphenicol 
or thiamphenicol, combinations of (3-lactam drugs with P-lactamase inhibitors (tazobactam, 
sulbactam or clavunic acid), and certain new quinolones such as trovafloxacin, clinafloxacin, 
moxyfloxacin, sitafloxacin and gemifloxacin. The main types of antibiotic resistance 
mechanisms are as follows: an altered affinity in target binding, a decreased permeability for 
the antibiotic, and the presence of an inactivating enzyme. 
In general, the 5-nitroimidazoles (5-NI) and carbapenems are the classes of the most 
active antimicrobial agents against the Bacteroides spp. Strains of Bacteroides spp. with 
resistance to imipenem or metronidazole have been isolated, but only rarely. 
2. AIMS 
1. To examine the prevalence of toxin-producing C. difficile in faecal samples of 
inpatients who suffer from diarrhoea during their hospital stay in a 1200-bed 
university hospital in Hungary. To evaluate the ordering patterns of Hungarian 
physicians for the C. difficile toxin-determination tests and their impact on the 
laboratory results and therefore on the clinical diagnosis, results obtained on stool 
specimens for which C. difficile had been specifically requested were compared with 
those for which it had not. 
2. To collect clinically relevant isolates of C. difficile from different hospital wards in the 
same hospital, in order 1) to determine whether these isolates are genetically similar to 
C. difficile isolates collected in the UK by the ARU in Cardiff; and 2) to identify the 
most common ribotypes of C. difficile in our hospital, in Szeged. 
3. To determine the prevalence of the nim resistance genes among clinical isolates from 
Bacteroides spp. in Hungary and to characterize the different types of nim genes. 
4. To determine the presence of the cfiA gene by means of PCR in clinical isolates and 
the normal faecal flora of B.fragilis collected in Hungary. 
5. To use a PCR-RFLP technique for the reliable identification of clinically important 
Bacteroides strains at the species level. 
3. MATERIALS AND METHODS 
Epidemiological investigation of C. difficile 
Bacterial strains 
During a one-year period, 3 081 faecal samples were screened for bacterial enteric 
pathogens. The samples originated from different hospital wards of the University Hospital of 
Szeged. Two different groups of samples were investigated for the presence of C. difficile 
toxin: the first group consisted of samples where clinicians had specifically requested the 
investigation of C. difficile toxin (n=375). In these cases, the presence of toxin A was 
determined by using the VIDAS (bioM6rieux, France) toxin detection kit. The second group 
consisted of 570 stool samples which were selected by different selection criteria in the 
laboratory in order to investigate the presence of the "free toxin" in the faeces by use of a 
cytotoxin assay. The selection criteria were: long-stay hospitalization (>5 days), loose, liquid 
stools (bloody or/and mucoid), lack of other enteric pathogenic bacteria, viruses, ova or 
parasites, and from the clinicians for no request C. difficile toxin investigation. 
Toxin testing 
Toxin B: Cytotoxin assay by tissue culture: Freshly-taken faecal samples were used 
for the standard procedure for the cytotoxin assay, using the HeLa cell line. Before use, the 
filtrates were diluted 1:10; 1:20; 1:40 and 1:80. 10 pi of each dilution was inoculated onto a 
HeLa cell monolayer, which was examined after an overnight incubation and again after 48 h. 
Toxin A: was determined by using the VIDAS (bioMerieux, France) toxin detection 
kit, according to the manufacturer's indtruction. 
PCR ribotyping of clinical isolates of C. difficile 
Bacterial strains 
Out of the 68 C. difficile isolates used in this study, 57 strains were isolated from 
diarrhoeal faecal samples and 8 originated from other clinical materials. Three reference 
strains were included as controls: C. difficile NCTC 11382 (toxin A-positive, toxin B-
positive), C. difficile CCUG 20309 (toxin A-negative, toxin B-positive) and C. difficile 
NCTC 11206 (toxin A-negative, toxin B-negative). Stool samples were cultured on 
selective CCFA (Wadsworth Manual) as soon as possible in the laboratoiy, and incubated at 
37 °C under anaerobic conditions (anaerobic chamber; Bactron Sheldon Man, Oregon USA) 
for 24-48 h. Other clinical materials were cultured on prereduced Columbia agar base (Oxoid, 
United Kingdom) supplemented with 5% cattle blood, vitamin Ki and haemin, and incubated 
at 37 °C under anaerobic conditions (anaerobic chamber; Bactron Sheldon Man, Oregon, 
USA) for 24-48 h. The identification of the isolates was based on the characteristic colonial 
morphology, green-yellow UV fluorescence (under UV light) and latex agglutination 
(MIcroScreen C. difficile Latex Slide Agglutination Test; Mercia Diagnostics, UK). 
PCR ribotyping method 
Isolates were cultured anaerobically overnight under anaerobic conditions on FAA 
supplemented with 6% horse blood. Approximately 10 colonies were picked, and crude 
template nucleic acid was prepared by the resuspension of cells in 5% (wt/vol) Chelex-100 
(Bio-Rad, Hemel Hempstead, United Kingdom) and boiled for 12 min. After the removal of 
cellular debris by centrifugation, 10 pi of supernatant was added to 90 pi of PCR mix. 
Amplification products were concentrated to a final volume of 25 pi by heating at 75 °C for 
90 min before electrophoresis. Electrophoresis was carried out at 100 mA and 200 V in 3% 
Metaphor agarose (EMC Bioproducts, Rockland, Maine) for 4.5 h, at 8 °C. Products were 
visualized by staining the gel for 20 min in ethidium bromide (0.5 pg/ml). To allow 
normalization of all gel patterns, a molecular size standard (100 bp; Advanced 
Biotechnologies, Epsom, United Kingdom) was run at 5-lane intervals. 
Primers 
PCR ribotyping uses specific primers complementary to the 3' end of the 16S rRNA 
gene and the 5' end of the 23S rRNA gene to amplify the variable-length intergenic spacer 
region. 
Analysis of banding patterns and library construction 
Gel images were analysed with GelCompar image analysis software (version 4.0; 
Applied Maths, Kortrijk, Belgium). The criterion for the proposal of a new library type was 
the existence of clearly discernible, reproducible differences in PCR ribotype pattern from 
those of all other existing types. 
Detection and characterization of turn genes of Bacteroides spp. 
Bacterial strains 
A total of 202 non-duplicate Bacteroides strains were collected from the different 
hospital wards of the 1200-bed University Hospital in Szeged during two years (2000 and 
2001). Bacteroides strains were cultured on prereduced Columbia agar base (Oxoid, United 
Kingdom) supplemented with 5% cattle blood, vitamin Ki and haemin, and incubated at 
37°C, under anaerobic conditions (anaerobic chamber; Bactron Sheldon Man, Oregon, USA) 
for 48 h. Routine phenotyping identification was carried out with the ATB ID 32A kit 
(bioM6rieux, S.A., Marcy l'Etoile, France). Quantitative determination of the metronidazole 
resistance of the strains was performed with E-test strips according to the manufacturer's 
instructions (AB Biodisk, Solna, Sweden) on Columbia agar. 
nim gene PCR 
The presence of nim genes in 18 strains that exhibited reduced sensitivity to 
metronidazole, and 1 strain which was high-level resistant to metronidazole, was assessed by 
PCR with the primers NIM-3 and NIM-5. Positive control strains containing nim genes 
included B. fragilis BF8 (nimB), B. fragilis 638R containing plasmid pIP417 (nimA), B. 
fragilis 638R containing plasmid pIP419 (nimC), and B. fragilis 638R containing plasmid 
pIP421 (nimD). B. fragilis Kw 388/1 was used as a nimE control strain (confirmed previously 
by a Southern hybridization method) and B. fragilis NCTC 11295 was included as a nim 
gene-negative control. PCR products were resolved by agarose (1.5%) gel electrophoresis 
with a molecular weight standard (100 bp; Advanced Biotechnologies, Epsom, UK), stained 
with ethidium bromide (0.5 pg/ml) and visualized with UV light. 
RFLP analysis 
Amplification products from nim gene were treated with the restriction endonucleases 
HpaU and Taql, according to the manufacturer's instructions (Promega). Digestion products 
were resolved in Metaphor agarose (3.5%) (FMC Bioproducts) at 100 V in TAE (40 mM 
Tris-acetate buffer, 1 mM EDTA, pH 8.0) for 2.5 h and visualized under UV light after 
staining for 20 min with ethidium bromide (0.5 pg/ml). 
Detection and mapping of the activating IS elements 
The presence of the IS 1J 86 element was determined with the primer pairs IS1186A 
and IS1186B. IS1186 elements were mapped upstream of the nimA,B genes, using the NIM-5 
and IS1186A primers. The B. fragilis strain 638R carrying a pIP417 plasmid was used as a 
positive control in both experiments. The PCR products were detected in 0.8% agarose gels in 
TBE buffer (45 mM Tris-acetate, 1 mM EDTA, pH 8.26) containing 0.5 pg/ml ethidium 
bromide and visualized as above along a 100 bp-3 kb ladder fragment preparation (Fermentas, 
Vilnius, Lithuania). 
Plasmid isolation and Southern hybridization 
Plasmid DNA was isolated as described before, except that chloramphenicol was not 
added, and electrophoretized as described in the previous section. For molecular weight 
determination, as Escherichia coli V517 plasmid preparation was used. DNA blotting to 
Hybond N+ nylon membrane (Amersham Pharmacia Biotech, Amersham Place, Little 
Chalfont, UK) was performed as in, while the nimA PCR fragment labelling was carried out 
with the Gene Images Random Prime labelling kit (Amersham Pharmacia Biotech) as 
recommended by the supplier, and hybridization as recommended in the random prime 
labelling kit leaflet of the same company. Hybridized probes were detected with the CDP-
Star detection kit (Amersham Pharmacia Biotech). 
Detection of the carbanenemase gene (cfiA) among Bacteroid.es son. 
Bacterial strains and plasmids 
During the period 1998-2000, a total of 242 Bacteroides spp. isolates were studied by 
PCR for the presence of the carbapenem resistance determinant, the cfiA gene. Out of 242 
strains, 231 were randomly selected clinically significant isolates, 1 B. fragilis isolate 
originated from a prostatic-abscess of a dog, and 10 isolates were obtained from faecal 
samples from healthy subjects. Isolates were identified by conventional biochemical tests or 
with the Rapid ID 32A system (bioMerieux). B. fragilis NCTC 9344 (carbapenem-sensitive) 
and B. fragilis TAL 3636 (a metallo-P-lactamase producer) were included as controls. The 
pJST241 plasmid, carrying the cloned cfiA gene, was obtained from M.H. Malamy. The 
Qiagen mini plasmid purification kit (Qiagen Inc., Hilden, Germany) was used for plasmid 
isolation. 
Antibiotic resistance determination 
The MIC values of carbapenems were determined by the Etest (AB Biodisk, 
Stockholm, Sweden) on brain heart infusion (BHI) agar supplemented with yeast extract (5 
g/1), haemin (5 mg/1) and menadione (1 mg/1) according to the instructions of the 
manufacturer. MICs were read after incubation for 48h in an anaerobic environment (Bactron, 
Shell Lab., Cornelius, USA). 
Determination of the ^-lactamase and specific imipenemase activities 
(^-lactamase activity was determined quantitatively with nitrocefin (0.10 mM) in 50 
mM sodium phosphate buffer (pH 7.0,37 °C) by a spectrophotometry method. 
Investigation of outer membrane (OM) proteins 
OM proteins of selected B. fragilis strains were examined by a method based on that 
described by Carlone et al. 
Detection of eft A gene by PCR 
The PCR method was used to screen the isolates for the cfiA gene. Bacterial cells 
grown on the surface of BHI agar plates were suspended in water and boiled for 10 min. The 
supernatants of the centrifuged suspensions were used as template DNA. PCR products were 
visualized on agarose gels containing ethidium bromide under UV light, and their sizes were 
compared with those of a molecular weight marker (100 bp DNA ladder, Sigma) and the 
product generated from B. fragilis TAL3636 as a positive control. 
Southern blotting with a c//A-specific probe obtained from the PCR product of the 
pJST241 plasmid was used to confirm the PCR results. PCR products were resolved on 1% 
agarose gels and were transferred to Nylon membranes (Amersham, UK) by capillary 
transfer. Radioactive labelling of the probe was performed with the Amersham Megaprime 
random priming kit (Amersham, UK) under the conditions recommended by the supplier. 
Nucleotide sequencing of PCR products 
Before nucleotide sequencing, the amplified PCR products were ethanol-precipitated 
with 0.5 volume of 7.5 M ammonium acetate and 2.5 volumes of absolute ethanol at room 
temperature to remove unincorporated primers. DNA sequencing was performed with an 
automated sequencer (ABPrism model 373, Applied Biosystems, Inc.) with the AmpliTaq FS 
DyeDeoxy terminator cycle sequencing kit (Applied Biosystems). The obtained DNA 
sequence was compared with those of known Bacteroides carbapenemase genes with the 
BLAST client programme accessible from the Internet at the National Center for 
Biotechnology Information. 
16S rDNA PCR-RFLP analysis of Bacteroides SPP. 
Bacterial culturing and identification of strains 
Bacterial strains were cultured on FAA supplemented with 5% (vol/vol) horse blood in 
an anaerobic atmosphere (10% C02 and 10% H2 and N2) at 37 °C. A total of 96 well-
characterized strains, including the type strain of each species, were analysed. A further 4 
strains from different clinical samples that gave ambiguous results in phenotypic tests were 
analysed. Control strains were obtained from the National Collection of Type Cultures 
(NCTC) and the American Type Collection (ATCC). Routine phenotyping identification was 
carried out with the commercially available ATB API 20A kit (bioMerieux, France) and 
conventional biochemical methods according to the instructions of the VPI Manual. 
16S rDNA PCR method 
Crude template nucleic acid was prepared with GeneReleaser (Cambio, Cambridge, 
UK). A single colony harvested after overnight culturing on FAA was resuspended in 20 pi of 
TE buffer (10 mM Tris, 1 mM EDTA, pH 8.0). GeneReleaser (20 pi) was added, vortex-
mixed for 20 s, and treated for 6 min at full power in a microwave owen. 16S rDNA genes 
were amplified with the universal primers pA and pH. Template nucleic acid (5 pi) was 
included in a 50 pi PCR reaction mixture 0.2 pM of each primer, and 1U of Taq DNA 
polymerase [Promega, Madison, Wisconsin, USA]). 
PCR products were resolved by agarose (1.5%) gel electrophoresis with a molecular weight 
standard (100 bp, Advanced Biotechnologies, Epsom UK), stained with ethidium bromide 
(0.5 pg/ml), and visualized with UV light. 
RFLP analysis 
Amplification products from 16S rDNA PCR were treated with the restriction 
endonucleases HpaU and TaqI, according to the manufacturer's instructions (Promega). 
Digestion products were resolved in Metaphor agarose 3% [wt/vol], FMC Bioproducts) at 100 
V in TAE (40 mM Tris-acetate buffer, 1 mM EDTA, pH 8.0) for 2.5 h and visualized with 
UV light after staining for 20 min with ethidium bromide (0.5 pg/ml). To allow normalization 
of RFLP patterns, a molecular weight standard (100 bp, Advanced Biotechnologies, Epsom, 
UK) was run at 5-line intervals. Restriction profiles were analysed with GelCompar (Applied 
Maths, Kortjik, Belgium). 
4. RESULTS AD DISCUSSION 
Prevalence of C. difficile diarrhoea in inpatients (Papers HI, IV and IX) 
During the study period (from April 1999 to March 2000), 3 081 faecal samples were 
screened for common bacterial enteric pathogens. All of these samples were from adult 
inpatients. 63 Salmonella (2.05%) and 4 Campylobacter (0.13%) isolates were found in the 
faecal samples of 67 patients. No isolates of other enteropathogenic bacteria (Yersinia sp., 
Shigella sp. or enteropathogenic E. coli) were found during this period. 
A total of 945 stool samples were investigated for the presence of C. difficile toxin, 
and 178 of them (18.9%) were toxin positive with one of the 2 toxin-detection methods. Only 
for 375 of the 945 stool samples obtained from the diarrhoeal patients had the clinicians 
requested C. difficile toxin testing, and 58 (18.3%) were toxin A-positive. Of the remaining 
570 samples, which fitted the selection criteria, 120 (21.05%) were toxin-positive by the 
cytotoxin assay. There was no significant difference in toxin-positivity rate (18.0% vs 
21.1%) between patients for whom C. difficile toxin testing was specifically requested and 
those for whom it was not. The overall positivity was 18.8% for those who became 
diarrhoeal during their stay in the hospital. 120 of the 178 patients who had C. difficile toxin-
positive stool specimens would have gone unnoticed if toxin testing had been carried out 
only for those for whom the physicians had requested it. Most of the toxin-positive patients 
were treated with P-lactam antibiotics, either in monotherapy or in combination, before the 
onset of the diarrhoea. This Hungarian survey should draw the attention of physicians to the 
role of C. difficile as a major nosocomial enteric pathogen in inpatients who have undergone 
antimicrobial treatment and/or surgery (especially gastrointestinal) and who have been 
subjected to a prolonged hospital stay. Our results support the finding of Bowman and Riley 
that infectious diarrhoea in hospitalized patients is more likely to be caused by C. difficile 
than by any other enteric pathogen, and laboratories should therefore include its investigation 
for their routine. 
Results of PCR ribotvping of C difficile (Paper Vim 
Analysis of the PCR ribotyping method was performed on a total of 57 faecal isolates 
from the symptomatic patients in different clinical units. Typing was also carried out on 8 
background strains selected from clinical cases. All of the isolates originated from different 
patients in various wards at the University Hospital of Szeged, none of them were 
outpatients. During a period of 3 months, 57 C. difficile strains were isolated from 252 faecal 
samples; 44 of them (77%) were toxin-producing. Six of the 8 clinical samples other than 
faeces collected during the same period (75%) were toxin-producing. A total of 15 different 
ribotypes were detected among the 65 isolates tested. The 50 (77%) toxigenic isolates could 
be classified into 7 visually distinct ribotypes, and the 15 non-toxigenic isolates into 8 PCR 
ribotypes. Of the 50 toxigenic isolates tested, 46 (92%) belonged in just 3 PCR ribotypes 
(087, 012 and 001), with type 087 being the most common, accounting for 50% (25 of 50) of 
the toxigenic isolates tested. The remaining 4 isolates (8%) belonged in 4 other ribotypes. 
There was a wider distribution among the ribotypes of non-toxigenic strains. A total of 15 
toxin-negative isolates were investigated in this study, and ribotype 009 was isolated most 
frequently (4/15). 2 non-toxigenic isolates belonging in ribotype 010 were isolated from 
conjunctiva and newborn faeces. 
All but 2 of the investigated isolates could be typed by this PCR ribotyping method; the 
exceptions were non-toxigenic isolates. These 2 isolates exhibited the same pattern, which 
was distinct from those of all the ribotypes described previously, suggesting that it is a new 
type. More investigations are required to classify it with the cluster correlation algorithm. 
Although this sample size is small, the isolates originating from Hungarian inpatients display 
a very different distribution of PCR ribotypes as compared with those found by the ARU in 
the UK. The most predominant ribotype in the Hungarian survey of 65 isolates was PCR 
ribotype 087, a toxigenic type, which accounted for 39% of all isolates. The prevalence of 
this ribotype in Hungary is in contrast with the findings in other countries: this type was not 
common in England and Wales, where only 8 isolates of this type were found among several 
thousand investigated isolates. Although no data have been published on the prevalence of 
C. difficile infection or the epidemiology of C. difficile-associated, diarrhoea in Hungary, the 
isolation of toxigenic C. difficile from hospitalized patients suggests that this pathogen is 
responsible for certain cases of diarrhoea of undiagnosed origin and validates our efforts to 
establish its significance in Hungary. 
Prevalence and characterization of mm genes of Bacteroides SPP. (Papers VII and X) 
A total of 202 non-duplicate isolates of Bacteroides spp. were isolated from different 
patients in various wards at the University Hospital of Szeged during the 2-year period. All 
of them, except one high-level metronidazole-resistant strain, were susceptible to 
metronidazole (NCCLS resistance breakpoint 32 pg/ml), but 4 of them (2.4%) in 2000 and 
14 (7%) in 2001 exhibited reduced sensitivity. The MIC90 was 1.0 pg/ml in both years. 
The control strains containing the 5 nim genes all gave good visible PCR product with 
a length 458 bp. Of the 19 clinical strains analysed, 3 gave PCR product with primers NIM-3 
and NIM-5. No PCR product was found for the other 16 strains which showed reduced 
sensitivity to metronidazole. The 5 different nim gene PCR products from the control strains 
produced unique digestion profiles with HpaU and Taql. PCR products from nim genes in 3 
clinical strains were identified by comparison of the digestion patterns with those from the 5 
nim genes from the control strains. B. fragilis 19924, gave a metronidazole MIC of 12 pg/ml, 
had a PCR RFLP profile consistent with nimA, and the B. fragilis 29877/1 with a 
metronidazole MIC of 4 pg/ml, had a PCR RFLP profile consistent with nimB gene. B. 
fragilis 20384, gave a high-level metronidazole MIC (>256 pg/ml) and had a PCR RFLP 
profile consistent with nimE. In addition to the nim gene types, the presence of the activating 
15 elements was also determined. With IS 1186 specific primers, the IS1186 element was 
demonstrated in the genomes of the m/n-positive strains; then, with one forward primer of the 
IS1186 element (IS1186A primer) and a reverse primer from the nim genes (NIM-5), the 
localization of the IS1186 elements was proved to be close enough and in correct orientation 
upstream of the nimA and nimB genes to activate them both in moderately-resistant B. fragilis 
strains. The plasmid profiles of the 2 mm-positive strains were also examined by the method 
used previously in our laboratory. In the strain B. fragilis 19924, a single plasmid of 7.7 kb 
was detected, while in the strains B. fragilis 29877/1 and 20384 (harbouring nimB and nimE, 
respectively), no plasmid could be found, during Southern hybridization of the non-
radioactively labelled nimA probe hybridised to the 7.7 kb plasmid from B. fragilis 19924. 
Metronidazole is the first drug of choice for the empirical coverage of anaerobic 
infections. The first B. fragilis strain resistant to metronidazole was reported by Ingham et al. 
in 1978. The articles published during the 1980s revealed only a few cases of B. fragilis that 
were resistant to metronidazole, and investigations into resistant strains and transmission 
mechanisms of resistance are reported only rarely. The true incidence of metronidazole 
resistance in Hungary is probably underestimated, since the antimicrobial sensitivity testing of 
anaerobes is not performed routinely in most routine laboratories. Diagnostic laboratories 
must also take note of the existence of artefactual resistance to metronidazole of Bacteroides 
spp., false resistance associated with susceptibility testing under suboptimal anaerobic 
conditions. Monitoring of the susceptibility of clinical isolates of anaerobes, preferably by 
MIC determination under well-controlled anaerobic conditions, is necessary as one means of 
assessing the situation. In a previous study, none of the clinical isolates belonging in the 
family Bacteriodaceae that were obtained during a 10-year period (1987-1997) were found to 
be resistant to metronidazole in Hungary. During the present study, we detected the first high-
level metronidazole-resistant strain and the first intermediate-resistant strains harbouring the 
metronidazole resistance determinant, the nim gene, in Hungary. The extent of metronidazole 
resistance in Bacteroides spp. is a most important issue, with profound implications for 
treatment. The presence of moderately metronidazole-resistant Bacteroides is difficult to 
detect by conventional susceptibility testing methods. We therefore need to continue to 
survey the antibiotic resistance among clinical isolates of Bacteroides spp. and screen for 
the presence of nim resistance genes. 
Prevalence of cfiA gene of Bacteroides spp. (Papers I. II. V. VI and VII) 
No expressed resistance to carbapenems was detected during the previous Hungarian 
resistance surveillances between 1987 and 1997, published by our laboratory. During the 
period 1998-2000, a total of 242 Bacteroides isolates were studied by PCR for the presence 
of the carbapenemase determinant, the cfiA gene. 2 B. fragilis isolates were included (both 
were isolated in 2000) which were found to be highly resistant to imipenem (MICs >256 
pg/ml) and meropenem (MICs >32 pg/ml) by susceptibility testing. A 729 bp cfiA gene 
fragment was detected in 5 carbapenem-sensitive B. fragilis isolates (MICs 0.06-1.5 pg/ml), 
in 2 imipenem-resistant strains, and in none of the non-fragilis isolates by PCR. Out of the 5 
c/L4-positive, but carbapenem-sensitive isolates, 4 had very low carbapenem MICs (0.06-
0.25 pg/ml), with almost no differences between imipenem and meropenem. Very low p-
lactamase activities were measured for these isolates. PAGE analysis of the OM proteins of 
the B. fragilis isolates with elevated MICs and those that were fully susceptible, but harboured 
the cfiA gene, did not reveal differences. The amplification of the regions upstream of the cfiA 
genes showed that no insertion occurred for the 5 sensitive isolates harbouring the 'silent' 
cfiA genes (amplification products of ca 300 bp found). The presence of 5 well-known IS 
elements (IS942, IS 1186, IS4351, IS/769 and IS//70) in the genome of these ^-posi t ive 
isolates was also investigated. No IS was detected among the carbapenem-sensitive strains, 
with one exception (B. fragilis 29877/1), which is moderately metronidazole-resistant and 
contains IS 1186. Southern blotting of the PCR products revealed homology to the probe 
from pJST241 plasmid (cfiA) in 3 isolates (B. fragilis isolates 20, 72 and 98). The PCR 
product of B. fragilis isolate 22 did not hybridize. Sequence analysis of the PCR product of B. 
fragilis isolate 22 showed that the 729 bp fragment bears ca 96% homology to the known cfiA 
genes. In the cases of the 2 resistant strains, the molecular background was further analysed 
together with the specific imipenemase activities. DNA upstream of the cfiA in these strains 
was amplified by PCR: the primer upstream of the gene was derived from a conserved region, 
oligonucleotide G, and the downstream primer comprised the complementary sequence 565-
598 within cfiA. Gel electrophoresis revealed upstream PCR products of 1.8 kb with these 
resistant strains. This suggested the insertion of an element of ca 1.5 kb upstream of the cfiA 
gene in both of the resistant strains. The presence of IS942 (1.59 kb) was detected in the 
genome in these strains, by PCR with IS element-type specific primers. The orientation and 
position of IS942 relative to cfiA were examined by PCR mapping. A PCR product of 2.2 kb 
was obtained, identical to that exhibited by B. fragilis TAL3636, which indicated the 
"correct" orientation of IS942 and its position upstream and adjacent to cfiA. This showed 
that IS942 had the potential to act as a functional promoter in these isolates. The P-lactamase 
and specific imipenemase production of the -positive isolates were determined. 4 of the 5 
isolates with low imipenem MICs produced low amounts of |3-lactamases, and the 2 resistant 
isolates produced high amounts of carbapenemase. 
These results show that care should be taken in Hungary too as regards the emergence 
of carbapenem-resistant Bacteroides strains, because the prevalence of 'silent' strains is 
relatively high and imipenem-resistant strains could arise. Moreover, the expressed resistant 
cases should befollow up because of therapeutic considerations. 
At present, few Bacteroides strains have been reported to harbour the cfiA gene and/or 
express metallo-p-lactamase production resulting in carbapenem resistance to the strains and 
causing a possible failure of therapy. The presence of the cfiA gene in B. fragilis isolates from 
faecal flora and in faecal samples was likewise confirmed by Fang et al., and other species 
than B. fragilis have also been isolated with a high-level production of metallo-P-lactamase. 
Careful following of the changes in the imipenem resistance of Bacteroides strains isolated 
from clinical samples and from normal faecal flora may be important, together with regular 
screening for the cfiA gene in these isolates. The high numbers of Bacteroides isolates which 
exhibit a reduced susceptibility to imipenem that have been reported in different studies, 
including ours, may draw attention to a probable decrease in the resistance breakpoint of 
imipenem. 
16S rDNA PCR-RFLP analysis of Bacteroides SPP. 
All but 2 of the type strains were identified correctly by the conventional biochemical 
methods. The type strains of B. merdae and B. distasonis could not be distinguished reliably 
by routine phenotypic methods because larch arabinogalactan is no longer available. Of the 84 
clinical strains analysed, 59 (70%) were identified unequivocally, 21 (25%) gave weak 
reactions for some critical biochemical tests (weak indole reactions, and variable fermentation 
reactions) and were identified only on repeat testing, and a further 4 (5%) could not be 
assigned reliably to a recognized species. 
The HpaTL profiles allowed the 12 investigated type strains to be differentiated into 8 
groups, while Taql differentiated them into 11 groups. All the type strains could be separated 
by using the two-enzyme strategy, and comparison with the reference profiles permitted 
unequivocal identification of 81 (96.5%) of the 84 clinical strains. Out of 8 strains which were 
not identified correctly phenotypically because of the weak biochemical reactions, 6 were 
identified as B. ovatus, 1 as B. thetaiotaomicron, and 1 as B. distasonis by 16S rDNA PCR-
RFLP identification. In the present study, the types generated by the combination of Taql and 
Hpall endonuclease digestion profiles correlated well with the findings obtained by 
conventional biochemical methods and the API 20A method, and allowed the identification of 
the clinical strains at the species level. Initial phenotypic identification was accurate for only 
70% of the isolates. When species were represented by single reference strains, all strains 
gave distinct profiles, and none was misidentified. The 16S rDNA PCR-RFLP approach 
offered an alternative to conventional methods, permitting the accurate grouping of strains 
and identification of Bacteroides spp. strains at species level. In conclusion, this method has 
been shown to be a simple, rapid, cost-effective, and highly discriminatory method for the 
identification of Bacteroides spp. of clinical origin. 
6. CONCLUSIONS 
1. For the first time in Hungary, we have investigated and published the epidemiology 
of C. difficile diarrhoea in hospitalized patients. The overall C. difficile toxin-positivity rate 
was 18.8% for those who contracted diarrhoea during their stay in the University Hospital of 
Szeged. There was no significant difference in toxin positivity rates between patients for 
whom C. difficile toxin testing had been specifically requested and those for whom it had not. 
The results of this study clearly demonstrated that infectious diarrhoea in hospitalized 
patients is more likely to be caused by C. difficile than by any other enteric pathogen. 
2. A retrospective study involving molecular characterization of case isolates of C. 
difficile was performed to delineate endemic strains in our hospital. A comparison of the 
ribotypes of nosocomial C. difficile isolates originating from different patients in Szeged, 
Hungary, with the library of C. difficile ribotypes in the ARU, UK, revealed a very different 
distribution of PCR ribotypes. The most predominant ribotype in our Hungarian survey of C. 
difficile isolates was PCR ribotype 087, a toxigenic type, which accounted for 39% of all 
isolates, in contrast with an international typing study, where its prevalence was much lower. 
The prevalence of this ribotype in Hungary is in contrast with the findings in some other 
countries, where the most common ribotype is ribotype 1. A previously unrecognized type 
was found in this study. 
3. In this study, the first high-level metronidazole-resistant Bacteroides strain and the 
first intermediate-resistant Bacteroides strains were found and published in Hungary, 
harbouring the metronidazole resistance determinant, the nim gene. The prevalence of the nim 
resistance genes among our clinical isolates from Bacteroides spp. was 1.5%. We 
characterized the nim genes which were found: the nimA and the nimB gene were detected in 
the intermediate-resistant strains, both of them harbouring the upstream copies of the 
IS1186/IS1168 element. A newly recognized nim gene (nimE) was present in our high-level 
metronidazole-resistant strain. 
4. For the first time in Hungary, this study investigated the prevalence of the 
carbapenemase gene of the clinical isolates of Bacteroides. 2.91% of the Bacteroides spp. 
obtained from different parts of Hungary possessed the cfiA gene. The survey on the 
occurence of 'silent', but q/M-positive, and phenotypically resistant B. fragilis isolates 
demonstrated their low prevalence (0.8%) in Hungary. These strains probably comprise a 
distinct subspecies of B. fragilis: IS942 was confirmed in the right position upstream of the 
cfiA gene in the carbapenem-resistant strains. 
5. We developed amplified 16S ribosomal DNA restriction analysis for identification 
of the species level of Bacteroides in Hungary. This method offered an alternative to 
conventional methods, permitting the accurate grouping of strains. 
Communications connected with the thesis 
I. Sóki József, Urbán Edit, Szőke Ildikó, Fodor Eleonóra, Nagy Erzsébet: 
Prevalence of the carbapenemase gene (cfiA) among clinical and normal flora isolates of 
Bacteroides in Hungary 
J. Medical Microbiology, 49:427-430 (2000) I.F.: 1.625 
II. Nagy Erzsébet, Sóki József, Edwards Rchard, Urbán Edit, Lajos Zoltán, Szabó Béla: 
Az első hazai carbapenemase termelésen alapuló imipenem rezisztens Bacteroides fragilis 
törzsek genetikai vizsgálata 
Infektológiai és Klinikai Mikrobiológia, 7:65-66 (2000) 
ffl. Urbán Edit, Terhes Gabriella, Nagy Erzsébet: 
Milyen gyakran kell számolni fekvőbeteg intézetben Clostridium difficile által okozott 
hasmenéssel? 
Infektológiai és Klinikai Mikrobiológia, 7:137-140 (2000) 
IV. Tusnádi Anna, Bakró Ildikó, Urbán Edit, Nagy Erzsébet: 
Clostridium difficile hasmenés két megyei kórházban. 
Infektológiai és Klinikai Mikrobiológia, 7:133-136 (2000) 
V. József Sóki, Richard Edwards, Edit Urbán, Eleonóra Fodor, Elisabeth Nagy: 
A clinical isolate of Bacteroides fragilis from Hungary with high-level resistance to 
imipenem 
J. Medical Microbiology, 50:107 (2001) LF.: 1.625 
VI. József Sóki, Richard Edwards, Zoltán Lajos, Tibor Vrabély, Eleonóra Fodor, Edit 
Urbán, Elisabeth Nagy: 
Isolation and characterisation of an imipenem-resistant Bacteroides fragilis strain from a 
prostate abscess in a dog 
Veterinary Microbiology, 84: 187-190 (2002) LF.: 1.428 
VII. Elisabeth Nagy, József Sóki, Edit Urbán, Ildikó Szőke, Eleonóra Fodor, Richard 
Edwards: 
Occurence of metronidazole and imipenem resistance among Bacteroides fragilis group 
clinical isolates in Hungary 
Acta Biologica Hungarica, 52:271-280 (2001) I.F.: 0.291 
VEH. Edit Urbán, Jon S. Brazier, József Sóki, Elisabeth Nagy, Brian I. Duerden: 
PCR-ribotyping of clinically important Clostridium difficile strains from Hungary 
J. Medical Microbiology, 50:1082-1086 (2001) I.F.: 1.625 
IX. Edit Urbán, Anna Tusnádi, Gabriella Terhes, Elisabeth Nagy: 
Prevalence of gastrointestinal disease caused by Clostridium difficile in a University 
Hospital in Hungary 
Journal of Hospital Infection 51:175-178 (2002) LF.: 1.812 
X. Edit Urbán, József Sóki, Jon S. Brazier, Elisabeth Nagy, Brian I. Duerden: 
Prevalence and characterization of nim genes of Bacteroides spp. isolated in Hungary 
Anaerobe (accepted for publication) I.F.: 0.410 
Acknowledgements 
I wish to express my special thanks to all those without whom this task would never have 
been fulfilled: 
I am greatly indebted to my supervisor, Professor Elisabeth Nagy, whose scientific 
guidance, encouragement and support over the past years have been invaluable and for 
which I am deeply obliged. 
I express my grateful thanks to Professor Brian I. Duerden, head of the Anaerobe 
Reference Unit in Cardiff, for his professionalism in his supervision of my study in 
Cardiff. 
I am very grateful to Dr. Jon S. Brazier for sharing with me his vast knowledge on the 
ribotyping method of C. difficile and the PCR method of nim gene. Special thanks are 
due to him for his untiring efforts and constant enthusiasm. 
I wish to thank Dr. Richard Edwards for his wide-ranging cooperation. 
I am especially grateful to all my coworkers, Dr. József Sóki, Dr. Eleonóra Fodor and 
Gabriella Terhes, for their helpful cooperation during our work. 
I am especially grateful to Anita Bönde and all the members of the staff of the 
Institute of Clinical Microbiology, whose indispensable technical assistance has 
contributed so much to this work. 
And last, but not least I wish to thank my family, my husband Ernő, my daughter Gerda 
and my son Ádám, for the love and support I have received during these years. 
